Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
Co-Founder and CEO Dr. Timothy Lu will deliver a presentation on September 8, 2025, at 2:00 PM ET in New York. The company's management will also be available for one-on-one meetings with qualified investors attending the conference. A live webcast of the presentation will be accessible through Senti Bio's website and archived for 90 days.
Senti Biosciences (Nasdaq: SNTI), azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie cellulari e geniche di nuova generazione, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference.
Il cofondatore e CEO Dr. Timothy Lu terr脿 una presentazione il 8 settembre 2025 alle 14:00 ET a New York. Il management sar脿 inoltre disponibile per incontri individuali con investitori qualificati presenti alla conferenza. La presentazione sar脿 trasmessa in diretta tramite il sito web di Senti Bio e rester脿 disponibile in archivio per 90 giorni.
Senti Biosciences (Nasdaq: SNTI), una compa帽铆a biotecnol贸gica en fase cl铆nica centrada en el desarrollo de terapias celulares y g茅nicas de nueva generaci贸n, anunci贸 su participaci贸n en la H.C. Wainwright 27th Annual Global Investment Conference.
El cofundador y CEO Dr. Timothy Lu ofrecer谩 una presentaci贸n el 8 de septiembre de 2025 a las 14:00 ET en Nueva York. La direcci贸n de la compa帽铆a tambi茅n estar谩 disponible para reuniones individuales con inversores cualificados asistentes a la conferencia. La presentaci贸n se emitir谩 en directo a trav茅s del sitio web de Senti Bio y quedar谩 archivada durante 90 d铆as.
Senti Biosciences (Nasdaq: SNTI)電� 彀劯雽� 靹疙彫 氚� 鞙犾爠鞛� 旃橂氩� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, H.C. Wainwright 27th Annual Global Investment Conference鞐� 彀戈岸捻暅雼り碃 氚滍憸頄堨姷雼堧嫟.
瓿惦彊 彀届梾鞛� 瓴� CEO鞚� Dr. Timothy Lu臧赌 2025雲� 9鞗� 8鞚� 鞓ろ泟 2鞁�(霃欕秬 響滌鞁�) 雺挫殨鞐愳劀 氚滍憸毳� 歆勴枆頃╇媹雼�. 須岇偓 瓴届榿歆勳潃 旎嵓霟办姢鞐� 彀胳劃頃� 鞝侁博 韴瀽鞛愲摛瓿检潣 鞚茧寑鞚� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 氚滍憸電� Senti Bio 鞗轨偓鞚错姼毳� 韱淀暣 霛检澊敫� 鞗箘旌愳姢韸鸽 鞝滉车霅橂┌ 90鞚缄皠 鞎勳勾鞚措笇搿� 氤搓磤霅╇媹雼�.
Senti Biosciences (Nasdaq: SNTI), une soci茅t茅 biotechnologique en phase clinique ax茅e sur le d茅veloppement de th茅rapies cellulaires et g茅niques de nouvelle g茅n茅ration, a annonc茅 sa participation 脿 la H.C. Wainwright 27th Annual Global Investment Conference.
Le cofondateur et PDG Dr. Timothy Lu fera une pr茅sentation le 8 septembre 2025 脿 14h00 ET 脿 New York. La direction de la soci茅t茅 sera 茅galement disponible pour des r茅unions individuelles avec des investisseurs qualifi茅s pr茅sents 脿 la conf茅rence. La pr茅sentation sera diffus茅e en direct sur le site web de Senti Bio et archiv茅e pendant 90 jours.
Senti Biosciences (Nasdaq: SNTI), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Next鈥慓eneration-Zell鈥� und Gentherapien spezialisiert hat, gab seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference bekannt.
Mitgr眉nder und CEO Dr. Timothy Lu wird am 8. September 2025 um 14:00 Uhr ET in New York eine Pr盲sentation halten. Das Management steht auch f眉r Einzelgespr盲che mit qualifizierten Investoren auf der Konferenz zur Verf眉gung. Die Pr盲sentation wird live 眉ber die Website von Senti Bio gestreamt und f眉r 90 Tage im Archiv verf眉gbar sein.
- None.
- None.
Live webcast presentation with Co-Founder and CEO, Dr. Timothy Lu, on September 8th at 2:00 PM ET
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (鈥淪enti Bio鈥�), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that of Senti, will present on Monday, September 8, 2025 at 2:00 PM ET at the being held in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference .
A of the presentation will be available on the page of the section of the Company鈥檚 website (). The webcast replay will be archived for 90 days following the event.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company鈥檚 wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti鈥檚 Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at or follow Senti Bio on (@SentiBio) and (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on and . The information that we post on our website or on or could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
FAQ
When is Senti Biosciences (SNTI) presenting at the H.C. Wainwright Conference?
Who will be presenting for Senti Biosciences at the H.C. Wainwright Conference?
How can investors access Senti Biosciences' H.C. Wainwright Conference presentation?
What type of meetings will Senti Biosciences management be available for at the conference?
